C S Vidhya Annapoorni, S R Chandra, Thomas Gregor Isaac
{"title":"COVID-19 Vaccine-triggered Relapsing Immune Dysregulation: An Observational Study with Four-year Follow-up.","authors":"C S Vidhya Annapoorni, S R Chandra, Thomas Gregor Isaac","doi":"10.1177/09727531261434290","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Vaccination against COVID-19 infection became mandatory because of the field situation during the pandemic.</p><p><strong>Purpose: </strong>Vaccine efficacy and safety need many field years of study; time constraints due to the pandemic limited the same. A hospital-based study was done in South India among patients who presented with immune-mediated disorders in temporal correlation with COVID-19 vaccination.</p><p><strong>Methods: </strong>The study period was 20 months, from March 2020 to November 2021. There were a total of 3,235 patients with neurological issues seen in two tertiary institutions, catering predominantly to patients from lower socio-economic strata in South India. A total of 1,007 (31.12%) patients had received COVID-19 vaccination (single dose in 511 [50.7%] and both doses in 496 [49.3%]). The general prevalence of primary demyelinating disease was compared with the background of vaccine-induced demyelination. Chi-square test was utilised for determining the association between neurological sequelae and the type of vaccine administered.</p><p><strong>Results: </strong>Eighteen patients had neurological sequelae, and 16 had a monophasic pattern. Recurrent autoimmunity was seen in two patients who took the Sputnik vaccine. Comparing the prevalence of primary multiple sclerosis (MS) versus vaccine-induced demyelination, there was a statistically significant difference (<i>χ</i> <sup>2</sup> = 572.38; <i>p</i> < .001), which indicates a definite role of vaccination in these patients. The association between neurological manifestations of Covishield and Covaxin showed no statistically significant difference in neurological sequelae (<i>χ</i> <sup>2</sup> = 0.0466; <i>p</i> = .8). The Sputnik vaccine was not considered, as the number was less than five. Anti-myelin oligodendrocyte glycoprotein-associated recurrent optic neuritis was seen in one patient, and tongue atrophy, pyramidal signs, ulcerative colitis and arthritis after 3 months, and C-ANCA positivity were seen following the Sputnik vaccine in one patient.</p><p><strong>Conclusion: </strong>Vaccination is an effective public health intervention. However, in susceptible individuals, it can probably trigger a recurrent and multisystem event by immune dysregulation. The association is an observation-based postulate that needs a longer, larger follow-up. As per this study, it is non-fatal and remits permanently.</p>","PeriodicalId":7921,"journal":{"name":"Annals of Neurosciences","volume":" ","pages":"09727531261434290"},"PeriodicalIF":3.1000,"publicationDate":"2026-06-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13314644/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annals of Neurosciences","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/09727531261434290","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"NEUROSCIENCES","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Vaccination against COVID-19 infection became mandatory because of the field situation during the pandemic.
Purpose: Vaccine efficacy and safety need many field years of study; time constraints due to the pandemic limited the same. A hospital-based study was done in South India among patients who presented with immune-mediated disorders in temporal correlation with COVID-19 vaccination.
Methods: The study period was 20 months, from March 2020 to November 2021. There were a total of 3,235 patients with neurological issues seen in two tertiary institutions, catering predominantly to patients from lower socio-economic strata in South India. A total of 1,007 (31.12%) patients had received COVID-19 vaccination (single dose in 511 [50.7%] and both doses in 496 [49.3%]). The general prevalence of primary demyelinating disease was compared with the background of vaccine-induced demyelination. Chi-square test was utilised for determining the association between neurological sequelae and the type of vaccine administered.
Results: Eighteen patients had neurological sequelae, and 16 had a monophasic pattern. Recurrent autoimmunity was seen in two patients who took the Sputnik vaccine. Comparing the prevalence of primary multiple sclerosis (MS) versus vaccine-induced demyelination, there was a statistically significant difference (χ2 = 572.38; p < .001), which indicates a definite role of vaccination in these patients. The association between neurological manifestations of Covishield and Covaxin showed no statistically significant difference in neurological sequelae (χ2 = 0.0466; p = .8). The Sputnik vaccine was not considered, as the number was less than five. Anti-myelin oligodendrocyte glycoprotein-associated recurrent optic neuritis was seen in one patient, and tongue atrophy, pyramidal signs, ulcerative colitis and arthritis after 3 months, and C-ANCA positivity were seen following the Sputnik vaccine in one patient.
Conclusion: Vaccination is an effective public health intervention. However, in susceptible individuals, it can probably trigger a recurrent and multisystem event by immune dysregulation. The association is an observation-based postulate that needs a longer, larger follow-up. As per this study, it is non-fatal and remits permanently.